Gilead Sciences, Inc. [NASDAQ: GILD] gained 0.23% or 0.15 points to close at $65.42 with a heavy trading volume of 12380268 shares. The daily chart for GILD points out that the company has recorded -16.55% loss over the past six months. If we look at
Gilead Sciences, Inc. [NASDAQ: GILD] stock went on an upward path that rose over 0.91% on Friday, amounting to a one-week price decrease of less than -1.92%. Over the last 12 months, GILD stock dropped by -20.63%. The one-year Gilead Sciences, Inc. stock forecast points
Gilead Sciences, Inc. [NASDAQ: GILD] loss -0.47% or -0.32 points to close at $67.75 with a heavy trading volume of 7712556 shares. The daily chart for GILD points out that the company has recorded -11.74% loss over the past six months. If we look at
Gilead Sciences, Inc. [NASDAQ: GILD] closed the trading session at $69.94. The company report on April 8, 2024 at 4:05 PM that Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024. Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its
Gilead Sciences, Inc. [NASDAQ: GILD] loss -1.08% on the last trading session, reaching $72.09 price per share at the time. The company report on March 28, 2024 at 8:30 AM that FDA Expands Indication for Gilead’s Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in
Gilead Sciences, Inc. [NASDAQ: GILD] stock went on an upward path that rose over 0.83% on Wednesday, amounting to a one-week price decrease of less than -1.31%. The company report on March 26, 2024 at 9:15 AM that Winn Awards Help Physicians Solve Healthcare Disparities.
Gilead Sciences, Inc. [NASDAQ: GILD] slipped around -0.43 points on Monday, while shares priced at $73.26 at the close of the session, down -0.58%. The company report on March 18, 2024 at 7:29 PM that Center for Disease Analysis Foundation Announces First Round of Grantees
Gilead Sciences, Inc. [NASDAQ: GILD] stock went on an upward path that rose over 0.27% on Monday, amounting to a one-week price increase of more than 4.25%. The company report on March 11, 2024 at 8:24 AM that Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting
Gilead Sciences, Inc. [NASDAQ: GILD] gained 1.02% or 0.74 points to close at $72.99 with a heavy trading volume of 6276524 shares. The company report on March 5, 2024 at 4:35 PM that New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People
Gilead Sciences, Inc. [NASDAQ: GILD] gained 0.10% or 0.07 points to close at $73.02 with a heavy trading volume of 6057572 shares. The company report on February 27, 2024 at 10:00 AM that Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity
© 2024, Powered by Smart TechOne
